Hepatocellular Carcinoma: Causes and Prevention

Noha E. Ibrahim1, Wael M. Aboulthana2* and Ram Kumar Sahu3

1Microbial Biotechnology Department, Genetic Engineering and Biotechnology Division, National Research Centre, 33 Bohouth St., P.O. 12622, Dokki, Giza, Egypt (Affiliation ID: 60014618)

2Biochemistry Department, Genetic Engineering and Biotechnology Division, National Research Centre, 33 Bohouth St., P.O. 12622, Dokki, Giza, Egypt (Affiliation ID: 60014618)

3University College of Pharmacy, Pt. Deendayal Upadhyay Memorial Health Sciences and Ayush University of Chhattisgarh, Raipur (C.G.), India

Received: 11-Jul-2018 , Accepted: 23-Oct-2018

Keywords: Hepatocellular Carcinoma, Hepatitis, Viral Infection, Aflatoxin, Vaccination

Full-Text PDF      

Google Scholar  

How To Cite       

Abstract

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. It is considered as the second leading cause of cancer-related death worldwide with over 500,000 people affected. Incidence of the HCC is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and C strongly predisposes to development of the chronic liver disease and subsequent development of HCC. In most cases, the cause of liver cancer is long-term damage and scarring of the liver cirrhosis that may be caused by viral infections (Virus B or C) or non-viral causes such as non-Alcoholic Fatty Liver Disease (NAFLD), autoimmune diseases, inflammation of the liver (chronic), obesity, diabetes, alcohol consumption, smoking, iron overload in the body (hemochromatosis) and the exposure to aflatoxin. The recent studies concluded that vaccination and the antiviral treatment are the most important ways for the HCC prevention.

1 Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy that is considered as the second leading cause of cancer-related death worldwide1. The studies which were carried out with over half a million new cases diagnosed annually worldwide, it was reported that HCC is the fifth most common cancer in men and seventh among women2. The HCC is particularly lethal with a 5-year survival of less than 5%of thepatients who are not transplant candidates3. A total of 30 new liver cancers and 640 intrahepatic bile duct cancers were estimated during 20134. In 2010, Ferlay et al.5 documented that HCC occurred more often in males than females (2.4:1) with a higher incidence in Eastern and Southern Asia, Middle and Western Africa, Melanesia and Micronesia/Polynesia.

Moreover, it was found that the age-adjusted incidence of liver cancer has risen from 1.6 per 100,000 individuals to 4.6 per 100,000 individuals among American Indians and Alaskan Natives followed by blacks, whites and hispanics6. In the United States, incidence of the HCC increases with a more than two fold from 1976 to 20027-9. A significant proportion of this increase is accounted for by the growing prevalence of hepatitis C virus (HCV) infection10. However, other potential causes of HCC are garnering close attention. Increased body mass index and diabetes with subsequent development of non-alcoholic steatohepatitis (NASH) represent significant risk factors for incidence of HCC. This is especially concerning in light of the growing epidemic of obesity in adults and children over the past 25 years7,10-13.

Other non viral causes of HCC include iron overload syndromes, alcohol use, tobacco use, oral contraceptive use, aflatoxin exposure and betel quid chewing, a prevalent habit in the world. Emerging evidence suggests that etiology of many cases of HCC is in fact multifactorial, including both viral infections and non-viral environmental and dietary exposures (Fig 1).

2 Viral causes of hepatocellular carcinoma

2.1 Hepatitis B Virus (HBV)

Hepatitis B virus (HBV) is a double-stranded, circular DNA molecule with eight genotypes (A to H). Genotypes A and D are more common in Europe and the Middle East, while genotypes B and C are more common in Asia14. Hepatitis B is transmitted via contaminated blood transfusions, intravenous injections and sexual contact. Vertical transmission from mother to fetus is the leading cause for HBV infection worldwide. Five percent of the world’s population is infected with hepatitis B15. HBV is the leading risk factor for HCC globally and accounts for at least 50% cases of HCC16. In endemic areas, HBV is mostly acquired by vertical and perinatal transmission with > 90% of these cases becoming chronic HBV carriers.

In contrast, areas of low prevalence such as western countries, it is usually acquired in adulthood by horizontal transmission (through sexual and parenteral routes) with >90% of acute infections resolving spontaneously. HBV is a notorious HCC cause in the absence of cirrhosis; however, most (70%-90%) HBV-related HCC develops in cirrhotic livers17. Several factors have been reported to increase HCC risk among HBV carriers, including demographic (male gender, older age, Asian or African ancestry, family history of HCC), viral (higher levels of HBV replication, HBV genotype, longer duration of infection, co-infection with HCV, HIV or HDV), clinical (cirrhosis) and environmental or life-style factors (exposure to aflatoxin, heavy alcohol drinking or tobacco smoking). In Asian studies, genotype C is associated with more severe liver disease, cirrhosis and the development of HCC, compared with genotype B; whereas in Western Europe and North America, genotype D is more associated with a higher incidence of HCC than genotype A, as well as the development of HCC in young carriers without cirrhosis18.

2.2 Hepatitis C Virus (HCV)

Hepatitis C virus (HCV) is a small, single-stranded RNAvirus, which exhibits high genetic variability19. There are six different genotypes of HCV isolated. Genotypes I, II and III are predominant in the Western countries and the Far East, while type IV is predominant in the Middle East. The highest rates of chronic hepatitis C infection occur in Egypt (18%), with lower rates occur in Europe (0.5%-2.5%), the United States (1.8%) and Canada (0.8%)20. Once infected with HCV, 80% of patients progress to chronic hepatitis, with ~20% developing cirrhosis21. In hepatitis C, the HCC development occurs almost exclusively in the liver with established cirrhosis. HCV increases risk of the HCC by inducing hepatic inflammation and importantly fibrosis, but also promoting malignant transformation of infected cells22. Other risk factors that increase risk of HCC in infected patients include male sex, co-infection with HIV, HBV, HCV genotype 1b, old age, presence of diabetes and obesity, and a high level of chronic alcohol consumption. But, the risk of HCC is reduced significantly in patients who obtained a sustained viral response after treatment of HCV with a 54% reduction in all-cause mortality23.

3 Non-viral causes of hepatocellular carcinoma

3.1 Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries, with ~20% of individuals affected24. It occurs in absence of alcohol use, although the hepatic histology appears consistent with alcoholic hepatitis25, with changes in histology including hepatic steatosis, inflammation, hepatocyte injury as exemplified by cytologic ballooning and Mallory’s hyaline and fibrosis26. Thus, NAFLD comprises a spectrum of conditions ranging from fat alone to fat plus inflammation and fat plus ballooning degeneration25, 27. Epidemiologic studies showed that NAFLD is closely linked with the metabolic syndrome, particularly type 2 diabetes mellitus and obesity28, with NAFLD occurring almost universally among diabetic patients who are morbidly obese29. Moreover, NASH in association with multiple components of the metabolic syndrome is thought to increase the risk for developing chronic liver disease, cirrhosis and HCC28.

Although the pathophysiologic mechanisms driving NAFLD and the associated progressive hepatocellular damage are not fully understood, a number of processes have been described. A well-established driver of NAFLD is Insulin Resistance (IR) (Fig 2). IR is a complex process that likely involves both insulin secretion and action, and is closely associated with obesity29. IR causes increased peripheral lipolysis and increases circulating fatty acids that are taken up by the liver. At the same time, there is an increase in de novo liponeogenesis in the hepatocytes and a reduction in the hepatic secretion of very-low-density lipoproteins, resulting in hepatic triglyceride accumulation or fatty liver. Increased intrahepatic fatty acid levels are also thought to provide a source of the oxidative stress which may play an important role in the development from steatosis to steatohepatitis associated with progression to cirrhosis30. The reactive oxygen species (ROS) produced by the mitochondria oxidize fat deposits to release lipid peroxidation products which together with ROS impair the respiratory chain via oxidative damage to the mitochondrial genome31. ROS and lipid peroxidation products also increase production of various cytokines including TNF-α, TGF-β and Fas ligand. Furthermore, the proinflammatory cytokines activate the hepatic stellate cells which produce a collagen matrix and drive the fibrosis development32.

3.2 Obesity

Prevalence of obesity has increased to epidemic proportions over the last three decades. Excess body mass is classified as overweight if the BMI is > 25 kg/m2 and <30 kg/m2, or obese if the BMI is ≥ 30 kg/m2. In addition to the increase in an array of disease processes observed with being overweight or obese, both classifications of excess body mass are associated with a higher risk of developing all cancers including liver cancer33,34. In addition to an increased risk of developing HCC, overweight or obese patients appear to be at increased risk for HCC-related mortality. In a population-based study of cancer mortality and BMI, men with a BMI of 30-34.9 were found to have a two fold increase in the risk of death from HCC, with a 4.5-fold increase noted in men with BMI > 3533.

3.3 Diabetes

Diabetes has been found to increase the risk of developingchronic liver disease and HCC35. Diabetes mellitus directly affects the liver because of the essential role that the liver plays in glucose metabolism. It can lead to chronic hepatitis, fatty liver, liver failure and cirrhosis36,37. Patients with diabetes have between a 1.8- and 4-fold increased risk of HCC. As compared to HCV, NASH-related HCC liver transplants increased by nearly four times in the decade from 2002 to 201238. Hyperinsulinemia has been associated with a three fold increased risk of HCC. It is believed that the pleotropic effects of insulin that regulate the anti-inflammatory cascade and other pathways inducing cellular proliferation play a role incarcinogenesis. Insulin-like growth factor and insulin receptorsubstrate-1 promote cellular proliferation and inhibit apoptosis,respectively39,40.

3.4 Diet

Some studies have examined whether alterations in diethave an effect on the risk of HCC. A trial from Italy hasexamined a broad range of dietary habits among 185patients with HCC and 412 patients without cancer41,42. Those with HCC were more likely to consume a largeamount of calories, were five times more likely to beformer drinkers, and were 30 times more likely to beinfected with either HCV or hepatitis B virus (HBV).Among dietary compounds, consumption of iron andthiamine were associated with a significant threefoldand twofold increase in risk of HCC, respectively. Conversely,β-carotene and linoleic acid consumption wasassociated with a reduced risk of HCC41. Another study had been reported that the subjects with consumptionin the highest quartile for yogurt and milk, whitemeat and eggs had a significantly lower likelihood ofdeveloping HCC. This effect was observed in patientswith and without viral hepatitis43.

Other studies from Japan and Europe have found those who consume a large amount of green vegetables havea significantly lower likelihood of developing HCC44-46. One study has shown that eating green vegetables daily, ascompared with consumption fewer times per week, had aprotective effect against the development of HCC (OR:0.75, 95% CI: 0.60-0.95)44. On the contrary, a Greek studyhas found no association between vegetable intake and reductionin the risk of developing HCC47. So, there is evidence to suggest that consumptionof yogurt and milk as well as vitamin supplementsoffers a protective effect against HCC. The enthusiasmfor these findings however should be tempered bythe fact that the majority of these studies were retrospectivein nature48.

3.5 Coffee

Coffee consumption has also been studied and appears to have a potentially favorable effect on the prevention of liver diseases, including HCC49,50. There are several hypotheses that could explain why consuming coffee attenuates the risk of developing HCC. One hypothesis argues that coffee intake lowers serum levels of γ-glutamyltransferase (GGT), which is associated with a lower incidence of HCC50-53]. Coffee consumption has also been linked to a lower incidence of cirrhosis which is a major risk factor for the development of HCC50. In addition, coffee consumption lowers insulin levels and reduces the risk of diabetes, a known risk factors for HCC54. Animal studies also suggest that coffee contains compounds with anticarcinogenic properties. Chronic HCV patients who consumed high levels of coffee were found to have lower fibrosis score55. Ameta-analysis of studies on risk of HCC among coffee drinkers in European and Japanese studies showed a reduced risk of HCC. They concluded that relative risk of HCC among lowor moderate coffee drinkers (defined as 1-2 cups / day) was 0.70 (95% CI 0.57-0.85), andthat for high drinkers (defined as ≥ 3 cups / day) was 0.45 (95% CI 0.38-0.53) as comparedto non-drinkers56.

3.6 Alcohol

Alcohol consumption remains an important risk factorfor the development of HCC57. As illustrated in Fig 3, there is relationship between alcohol and liver disease and this correlates with amount of alcohol consumed over a lifetime, with heavy alcohol use rather than social drinking being the main risk of HCC58. The prevalence rate of alcohol abuse in the United States is five times higher than that of hepatitis C59. Alcohol abuse accounts for 40-50% of all HCC cases in Europe60. Studies in Europe reported an increase in the relative risk of developing liver disease above 7-13 drinks per week in women and 14-27 drinks per week in men59,61. In the United States, studies showed that the risk of liver cancer is increased two to four fold among persons drinking more than 60 g/d of ethanol62. A meta-analysis of 19 prospective studies showed that consumption of three or more drinks per day resulted in a 16% increase risk of liver cancer and consumption of six or more drinks per day resulted in a 22% increase risk63.

3.7 Smoking

Other risk factors may include smoking. Cigarette smoking is associated with a significant increase in the development of HCC. A recent meta-analysis that reviewed the association between smoking and liver cancer demonstrated an OR of 1.6 (95% confidence interval [CI], 1.3-1.9) for current smokers and 1.5 (95% CI, 1.1-2.1) for former smokers. Studies investigating the use of oral contraceptive pills and the risk for development of HCC have previously been inconclusive; however, a recent review of six studies showed a significant increase in HCC risk with a longer duration (>5 years) of exposure to oral contraceptives64.

3.8 Aflatoxin

Aflatoxin B1 (AFB1) is the major metabolite of the molds Aspergillus fumigatus and Aspergillus parasiticus. These moldsgrow on a variety of food products that are stored inwarm and damp conditions or are cultivated in countrieswith hot and humid climates65,66. AFB1 induces a singlenucleotide substitution in codon 249 in the p53 tumor suppressor gene, which results in the change of the aminoacid arginine to serine67,68. This mutation is present in upto 50% of patients with HCC who are indigenous to geographicregions with high exposure to AFB169-70.On theother hand, this mutation is absent in patients with HCC from regions with low exposure to AFB171,72. Moreover,it has been recently demonstrated that AFB1-albumin adductsin patients with HCC correlate significantly with thepresence of plasma DNA hypermethylation and mutationsin the p16 and p53 tumor suppressor genes73.

3.9 Host genetic factors

Host geneticmakeup may be an important factor that influences progression to HCC. Two meta-analysisindentified variants of tumor necrosis factor (TNF) associated with higher risk of HCC.They showed that TNFα-308 AA and AG variants (vs. GG) were associated with asignificantly increased risk of HCC74,75.

4 Prevention of HCC

As illustrated in Fig 4, prevention of HCC is an important goal and the opportunities exist for the further development of preventative measures76.

4.1 HBV vaccination

Development of HBV vaccine has been a major success in reducing the incidence of HBV infection and subsequent development of HCC. The vaccine is safe and effective against all HBV genotypes and serotypes. HBV vaccine is recommended for all newborns, pregnantwomen at their first pre-natal visit, and high-risk individuals. Neonates born to HBV infected mothers should get a dose of hepatitis B immune globulin in addition to vaccination. Countries like Taiwan that have implemented universal hepatitis B vaccination program have demonstrated its success. Twenty years after adopting the program, HBV carrier rate among children in Taiwan has decreased to 1.2% and incidence of HCC among the vaccinated children has dropped by 70%77.

4.2 Antiviral treatment

Antiviral treatment is also considered as one of the most important ways for the HCC prevention. A met analysis of non-randomized trials and observational studies demonstrated reduced risk of HCC after anti-viral treatment for HBV infection. A multicenter randomized controlled study on patients with chronic HBV and advanced hepatic fibrosis showed that 3.9% developed HCC on lamivudine therapy as compared to 7.4% in placebo arm when treated up to 5 years78.

In addition, the randomized and non-randomized studies have shown that achieving sustained viral response in chronic HCV patients, both with and without cirrhosis, leads to a substantial reduction in risk of HCC79,80. Although viremia of any level is a risk factor for HCC, viral load is not associated with HCC. HCV+ patients with advanced fibrosis who clear viremia with anti-viral treatment have a reduced, but not eliminated risk, of HCC and should undergo surveillance for HCC81.

5 Conclusion

The study concluded that cause of the liver cancer is long-term damage and scarring of the liver cirrhosis that may be caused by viral infections (Virus B or C) or non-viral causes such as NAFLD, autoimmune diseases, inflammation of the liver (chronic), obesity, diabetes, alcohol consumption, smoking, iron overload in the body and the exposure to aflatoxin. Furthermore, vaccination and the antiviral treatment are the most important ways for prevention of the HCC.

6 Conflict of interests

The authors declare that there is no conflict of interest among them and no any compelling interest exists.

7 Authors contributions

NEI collected ideas and information from previous review articles. WMA and RKS write the manuscript. Both of them read and approved the final form of manuscript. RKS communicated with journal’s editor to publish the manuscript. WMA carried out the corrections required.

8 References

  1. Center for Disease Control and Prevention (CDC). Hepatocellular carcinoma- United States 2001–2006. MMWR Morb Mortal Wkly Rep. 2010; 59(17):517-520.
  2. World Health Organization. Mortality Database. WHO Statistical Information System. 2008
  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340:745-750.
  4. Crissien AM, Frenette C. Current Management of hepatocellular carcinoma. Gastroenterol Hepatol. 2014;10(3):153-161.
  5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Int J Cancer. 2010;127(12):2893-2971.
  6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
  7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132: 2557-2576.
  8. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340:745-750.
  9. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003; 139: 817-823.
  10. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000; 160: 3227-3230.
  11. James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008; 263: 336-352.
  12. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004; 10: 69-S73.
  13. Schroeder SA. Shattuck Lecture. We can do better—improving the health of the American people. N Engl J Med. 2007; 357: 1221-1228.
  14. Bruix J, Sherman M. AASLD Practice Guidelines: management of hepatocellular carcinoma: an update. Hepatology. 2010:1-35.
  15. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212-2219.
  16. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030–3044.
  17. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, Therneau TM, Kim B, Roberts LR. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(1):64-70.
  18. Mittal S, El-Serag HB. Epidemiology of HCC: Consider the Population. J Clin Gastroenterol. 2013; 47(0): 2-6.
  19. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA.1991; 88(6):2451-2455.
  20. Bostan N, Mahmood T. An overview about hepatitis C: adevastating virus. Crit Rev Microbiol. 2010; 36(2):91-133.
  21. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am. 2013; 93(6):1423-1450
  22. Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012; 142:1274-1278.
  23. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158(5):329-337.
  24. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology. 2005; 42(1):44-52.
  25. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and naturalhistory of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001; 21(1):17-26.
  26. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2008; 24:320-327.
  27. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosisin patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-1362.
  28. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007; 7:175-180.
  29. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005; 172:899-905.
  30. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120(5):1183-1192.
  31. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004; 30(2):121-138.
  32. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005; 42:1339-1348.
  33. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625-1638.
  34. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, LaVecchia C, Serraino D, Franceschi S, Talamini R. The impactof obesity and diabetes mellitus on the risk of hepatocellularcarcinoma. Ann Oncol. 2009; 20: 353-357.
  35. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126: 460-468.
  36. Gao C, Fang L, Zhao HC, Li JT, Yao SK. Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a crosssectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int. 2013;12(4):385-393.
  37. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012; 130(7):1639-1648.
  38. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014; 59(6):2188-2195.
  39. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev. 1998; 7(2):89-107.
  40. Balkau B, Kahn H, Courbon D, Eschwege E, Ducimetiere P; Paris Prospective Study. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care. 2001; 24(5):843-849.
  41. Polesel J, Talamini R, Montella M, Maso LD, Crovatto M, Parpinel M, Izzo F, Tommasi LG, Serraino D, La Vecchia C, Franceschi S. Nutrients intake and the risk of hepatocellularcarcinoma in Italy. Eur J Cancer. 2007; 43: 2381-2387.
  42. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnosticlevel of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst. 2006; 98: 482-490.
  43. Talamini R, Polesel J, Montella M, Dal Maso L, Crispo A, Tommasi LG, Izzo F, Crovatto M, La Vecchia C, Franceschi S. Food groups and risk of hepatocellular carcinoma: Amulticenter case-control study in Italy. Int J Cancer. 2006; 119:2916-2921.
  44. Sauvaget C, Nagano J, Hayashi M, Spencer E, Shimizu Y, Allen N. Vegetables and fruit intake and cancer mortality in theHiroshima/Nagasaki Life Span Study. Br J Cancer. 2003; 88:689-694.
  45. La Vecchia C, Negri E, Decarli A, D’Avanzo B, Franceschi S.Risk factors for hepatocellular carcinoma in northern Italy. Int J Cancer. 1988; 42:872-876.
  46. Yu MW, Hsieh HH, Pan WH, Yang CS, CHen CJ. Vegetableconsumption, serum retinol level, and risk of hepatocellularcarcinoma. Cancer Res. 1995; 55:1301-1305.
  47. Kuper H, Tzonou A, Lagiou P, Mucci LA, Trichopoulos D, Stuver SO, Trichopoulou A. Diet and hepatocellular carcinoma:a case-control study in Greece. Nutr Cancer. 2000; 38: 6-12.
  48. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010; 16(29): 3603-3615.
  49. La Vecchia C, Tavani A. Coffee and cancer risk: an update. Eur J Cancer Prev. 2007; 16: 385-389.
  50. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, Lagiou P, Trichopoulos D. Does coffee protect against hepatocellular carcinoma?. Br J Cancer. 2002; 87: 956-959.
  51. Kono S, Shinchi K, Imanishi K, Todoroki I, Hatsuse K. Coffee and serum gamma-glutamyltransferase: a study of self defense officials in Japan. Am J Epidemiol. 1994; 139: 723-727.
  52. Tanaka K, Tokunaga S, Kono S, Tokudome S, Akamatsu T, Moriyama T, Zakouji H. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol. 1998; 27:438-443.
  53. Sharp DS, Everhart JE, Benowitz NL. Coffee, alcohol, and the liver. Ann Epidemiol. 1999; 9 :391-393.
  54. Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, Grobbee DE, Batty D, Woodward M. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med. 2009; 169(22):2053-2063.
  55. Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51(1):201-209.
  56. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, La Vecchia C. Coffee drinking and hepatocellular carcinoma risk: a meta- analysis. Hepatology. 2007; 46(2):430-435.
  57. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Alcohol Drinking. 1998; 44(44):207-215.
  58. Batey RG, Burns T, Benson RJ, Byth K. Alcohol consumption and the risk of cirrhosis. Med J Aust. 1992; 156:413-416.
  59. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004; 127(5):S87-S96.
  60. Jewell J, Sheron N. Trends in European liver death rates: implications for alcohol policy. Clin Med. 2010; 10(3):259-263.
  61. Brechot C, Nalpas B, Feitelson MA. Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med. 1996; 16:273-287.
  62. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002; 36(5): 1206-1213.
  63. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, Corrao G, Boffetta P, La Vecchia C. Alcohol and liver cancer: a systematicreview and meta-analysis of prospective studies. Ann Oncol. 2014; 25(8):1526-1535.
  64. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007; 47:506-513.
  65. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiologyand molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576.
  66. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006; 27: 2070-2082.
  67. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressorgene in human hepatocytes. Proc Natl Acad Sci USA. 1993; 90:8586-8590.
  68. Deng ZL, Ma Y. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World J Gastroenterol. 1998; 4: 28-29.
  69. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutationsof p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991; 350: 429-431.
  70. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, WangN, Shao Y, Wu Z, Liu G, Wang X, Sun Z. Dominant role ofhepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesisin Qidong, China. Hepatology. 2002; 36: 1214-1220.
  71. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignanthuman liver. Science. 1994; 264: 1317-1319.
  72. Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor-suppressor gene in hepatocellularcarcinomas from Britain. Hepatology. 1992; 16: 1362-1366.
  73. Zhang YJ, Rossner P Jr, Chen Y, Agrawal M, Wang Q, WangL, Ahsan H, Yu MW, Lee PH, Santella RM. Aflatoxin B1 andpolycyclic aromatic hydrocarbon adducts, p53 mutations andp16 methylation in liver tissue and plasma of hepatocellularcarcinoma patients. Int J Cancer. 2006; 119: 985-991.
  74. Guo YM, Wei WY, Shen XZ. Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Hepatogastroenterology. 2010; 57:926-931.
  75. Qin H, Liu B, Shi T, Liu Y, Sun Y, Ma Y. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: a meta-analysis. J Int Med Res. 2010; 38:760-768.
  76. Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res. 2009; 181:85-94.
  77. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008; 26:6266-6273.
  78. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advancedliver disease. N Engl J Med. 2004; 351:1521-1531.
  79. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response isassociated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.Clin Gastroenterol Hepatol. 2010; 8: 280-288.
  80. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(2):192–199.
  81. Mittal S, El-Serag HB. Epidemiology of HCC: Consider the Population. J Clin Gastroenterol. 2013; 47(0): 2-6.